| Literature DB >> 36175715 |
Theresa Schneider1, Lei Zhao2, Ziwen Zhu3, Gagik Gabrielyan1, Huaping Xiao1,4, Emerson D Fajardo3, Qian Bai3, Mark R Wakefield3, Yujiang Fang5,6.
Abstract
Bladder cancer is a prominent cancer worldwide with a relatively low survival rate for patients with increased stage and metastasis. Current treatments are based on surgical removal, bacillus Calmette-Guerin (BCG) Immunotherapy, and platinum-based chemotherapy. However, treatment resistance due to genetic instability of bladder tumors, as well as intolerance to treatment adverse effects leads to the necessity to further treatment options. New advancements in immunotherapy are on the rise for treatment of various cancers and specifically has shown promise in the treatment of bladder cancer. This review summarizes these new advancements in treatment options involving cytokines and cytokine blockade. Such a study might be helpful for urologists to manage patients with bladder cancer more effectively.Entities:
Keywords: Bladder tumor; Immunotherapy; Interleukin
Mesh：
Substances：
Year: 2022 PMID： 36175715 DOI： 10.1007/s12032-022-01828-3
Source DB: PubMed Journal: Med Oncol ISSN： 1357-0560 Impact factor: 3.738